Treatment perspectives for human African trypanosomiasis.
about
Chemotherapy for second-stage Human African trypanosomiasisChemotherapy for second-stage Human African trypanosomiasisNovel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasisNitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospectsTrypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leadsBis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.Influence of DNA structure on adjacent site cooperative binding.Selective inhibitors of trypanosomal uridylyl transferase RET1 establish druggability of RNA post-transcriptional modifications.The evolution of trypanosomatid taxonomy.Identification of stage biomarkers for human African trypanosomiasis.Dot enzyme-linked immunosorbent assay for more reliable staging of patients with Human African trypanosomiasis.Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.Importance of nonenteric protozoan infections in immunocompromised people.Parasitic infections in HIV infected individuals: diagnostic & therapeutic challengesUnderstanding mixed sequence DNA recognition by novel designed compounds: the kinetic and thermodynamic behavior of azabenzimidazole diamidinesEvaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1)Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei.Aromatic diamidines as antiparasitic agents.Hypocretin and human African trypanosomiasisPentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomesAn analogue-sensitive approach identifies basal body rotation and flagellum attachment zone elongation as key functions of PLK in Trypanosoma brucei.Antiparasitic compounds that target DNA.Viridamides A and B, lipodepsipeptides with antiprotozoal activity from the marine cyanobacterium Oscillatoria nigro-viridisAquaglyceroporins and metalloid transport: implications in human diseases.Immunolocalization and challenge studies using a recombinant Vibrio cholerae ghost expressing Trypanosoma brucei Ca(2+) ATPase (TBCA2) antigen.Chemoinformatic analysis as a tool for prioritization of trypanocidal marine derived lead compounds.Knockout and transgenic mice in glutathione transferase research.Neglected disease - african sleeping sickness: recent synthetic and modeling advances.Arsenic metabolism and thioarsenicals.Discovery of triazine mimetics as potent antileishmanial agents.The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei.In vitro investigation of the efficacy of novel diamidines against Trypanosoma cruzi.The transport of nifurtimox, an anti-trypanosomal drug, in an in vitro model of the human blood-brain barrier: evidence for involvement of breast cancer resistance protein.DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae.Synthesis and antiprotozoal activity of 2,5-bis[amidinoaryl]thiazoles.Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes.Minor groove binding compounds that jump a gc base pair and bind to adjacent AT base pair sites.Distribution of suramin, an antitrypanosomal drug, across the blood-brain and blood-cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice.Novel linear triaryl guanidines, N-substituted guanidines and potential prodrugs as antiprotozoal agents.
P2860
Q24201785-F12C8654-81C8-49E1-9D90-B6ED39D2368BQ24236290-A1893A71-27B0-4957-A7C1-99C93E9B96D9Q24311803-DE2E48FD-4C78-4B7D-8552-D6340A296F98Q26820381-8F3A7A56-D67B-4105-BA0F-F818A65E1A68Q26863285-5E051ED5-0E56-4956-982B-49B3DAC94AEEQ28477646-31FEFF33-5B3B-4697-8D51-E6F1A2A3B3F3Q33279371-021B24FE-F286-42C6-BFE0-B14988983368Q33346933-CFDAFB12-0435-43B7-96F6-75C4517C5CE5Q33739738-52050061-0B12-4184-8AD5-78C531FCE583Q33776260-82E33016-3C87-4D60-9419-F3FB9893B2BEQ33880764-1A3F7A7C-0C79-4059-AFDD-B3F20EBBBC38Q34042327-029D28A4-C6CF-439E-9BFF-171FC12E2AFAQ34113517-499D7930-4DEE-48A7-9FD8-9685BE63950DQ34189873-3E69D680-8F3A-4F82-B51F-4B60B7BA786DQ34635675-896ECBC4-20C2-4DC6-A2A8-0C9C328AC606Q35001202-B5E20F6A-1FDE-424E-8E85-E02218F7FE26Q35592068-A64C7746-BEEB-4A14-9AF8-D298DFBFD0EBQ35791902-A11796E5-6BB5-4D50-9AE6-B9DB7FCC6E39Q36210897-070132D3-D6DE-413C-8994-F412824B05ABQ36513244-C2D69CB8-34B2-4AAB-A569-2572497DA39AQ36684151-6D43B427-AD8B-4654-88A5-B04E62A8377EQ36803164-E07EB581-4527-4E89-B67D-623DE9C002BDQ36835020-F94707B6-B2F3-4CC2-B62F-50A2ED062890Q37130234-F8B5FCB1-4EB6-4FF7-AD28-0010E35630FCQ37310939-B21AD1A0-8553-4927-931C-2776FDC99C4FQ37450423-BB2A5F6C-7B93-4D81-BE97-379233C5AE0FQ37666958-01284F8D-73EF-4A4D-A505-071238453189Q37855792-6AF741E4-73AF-4F10-88B5-52CFE42C37A8Q37925570-2A983390-D839-4396-96A8-CD7D637E7577Q37987437-0A0DA4AC-7CF1-473C-B981-325A6C497B93Q38940416-F00C98E7-9FE6-442D-A811-7FD7DD78BDC7Q39160102-FE3E6986-77D6-48CE-BBE5-C9DDD0C9981BQ39209182-B6BFF98B-1689-47F8-A81A-EE7BAE90B243Q39422104-0C38C437-0968-472F-ABDE-00F8E0A4427FQ40164818-11DDCE62-793D-44FC-9424-7039229AAB75Q41453659-2608A1AD-97F5-4775-B1A7-4572594B95D9Q41824227-F78AA077-EB6D-4B6E-8895-2ECB47DCE2FDQ41936015-47A30782-968D-486E-86C1-A50EA316A845Q42627340-63C07C99-3610-4F88-8364-AA892966E021Q42924281-924B0933-0383-4779-8C2C-6612688114A6
P2860
Treatment perspectives for human African trypanosomiasis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Treatment perspectives for human African trypanosomiasis.
@ast
Treatment perspectives for human African trypanosomiasis.
@en
type
label
Treatment perspectives for human African trypanosomiasis.
@ast
Treatment perspectives for human African trypanosomiasis.
@en
prefLabel
Treatment perspectives for human African trypanosomiasis.
@ast
Treatment perspectives for human African trypanosomiasis.
@en
P2093
P2860
P1476
Treatment perspectives for human African trypanosomiasis.
@en
P2093
Bernard Bouteille
Michel Dumas
Odile Oukem
Sylvie Bisser
P2860
P304
P356
10.1046/J.1472-8206.2003.00167.X
P577
2003-04-01T00:00:00Z